MORF-057 clinical trials
Also written MORF-057 and LY4268989.
How each study uses MORF-057 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MORF-057 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (4)
Studies
Open first, then newest update. How each study uses MORF-057 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 2Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)NCT06226883Written as MORF-057
- A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UCCompletedPhase 2Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)NCT05611671Written as MORF-057
- A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UCCompletedPhase 2Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)NCT05291689Written as MORF-057
- Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy VolunteersCompletedPhase 1Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)NCT04580745Written as MORF-057